ArticlePloS one2026
Development of a novel scoring system to determine the optimal timing of esophagogastroduodenoscopy following portosystemic shunt occlusion.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Balloon-occluded retrograde transvenous obliteration (BRTO) is a safe and effective treatment for gastric varices (GV) and refractory hepatic encephalopathy (HE) associated with portosystemic shunt (PSS). However, esophageal varices (EV) worsening after BRTO is a major, postoperative complication. This study aimed to develop a novel scoring system for predicting EV deterioration following PSS occlusion and to determine the optimal timing for esophagogastroduodenoscopy (EGD) after the operation for patients with portal hypertension. We retrospectively analyzed data from 76 patients with PSS who underwent BRTO for GV or refractory HE [male/female = 39/37; Child-Pugh class A/B/C = 37/32/7; mean Hepatic venous pressure gradient = 10.8 mmHg] at our institution between April 2008 and March 2021. Factors associated with EV deterioration after BRTO were identified statistically. Cumulative rates of EV deterioration were determined using the Kaplan-Meier method. During a median follow-up period of 18.0 months, 50 patients experienced EV deterioration. The median time to EV deterioration was 23.4 months. Cumulative rates of EV deterioration at 12, 24, and 36 months were 35.5%, 51.5%, and 58.1%, respectively. Multivariate analysis using a Cox proportional hazards model identified male sex (p = 0.013), a preoperative platelet count ≤ 8.3x10⁴/μL (p = 0.032), and presence of EV before BRTO (p = 0.029) as significant independent risk factors for postoperative EV deterioration. Based on these three factors, we developed a novel scoring system ranging from 0-3 points. Median time to EV deterioration for scores 0, 1, 2, and 3 was unreached, 19.2, 10.2, and 6.5 months, respectively. Post-BRTO EV deterioration can be predicted using three factors: male sex, a preoperative platelet count ≤ 8.3x10⁴/μL, and the presence of EV before BRTO. This novel scoring system provides a structured approach for determining the optimal timing of EGD after BRTO, allowing risk stratification, improved postoperative patient management, early detection of EV deterioration, and timely endoscopic intervention for high-risk varices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.